Tech Company Financing Transactions
Unleash Immuno Oncolytics Funding Round
Private investors participated in a $25 thousand funding round for Unleash Immuno Oncolytics. The financing round was recorded on 3/31/2016.
Transaction Overview
Company Name
Announced On
3/31/2016
Transaction Type
Venture Equity
Amount
$25,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4320 Forest Park Ave. 304
Saint Louis, MO 63108
USA
Saint Louis, MO 63108
USA
Phone
Website
Email Address
Overview
Unleash Immuno Oncolytics, is an immune-oncology company developing oncolytic virus immunotherapy products to treat cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Katzman
Chief Operating Officer
Louis Cantolupo
Chief Scientific Officer
David Curiel
VP - Bus. Development
Bradley Keller
Browse more venture capital transactions:
Prev: 3/31/2016: RiboNova venture capital transaction
Next: 3/31/2016: Bento venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs